CN102647994A - 预防或治疗代谢综合症的方法 - Google Patents

预防或治疗代谢综合症的方法 Download PDF

Info

Publication number
CN102647994A
CN102647994A CN2010800461915A CN201080046191A CN102647994A CN 102647994 A CN102647994 A CN 102647994A CN 2010800461915 A CN2010800461915 A CN 2010800461915A CN 201080046191 A CN201080046191 A CN 201080046191A CN 102647994 A CN102647994 A CN 102647994A
Authority
CN
China
Prior art keywords
peptide
metabolic syndrome
arg
lys
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800461915A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·司徒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Priority to CN201710423699.6A priority Critical patent/CN107412724A/zh
Priority to CN201510230758.9A priority patent/CN105031605A/zh
Publication of CN102647994A publication Critical patent/CN102647994A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2010800461915A 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法 Pending CN102647994A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710423699.6A CN107412724A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法
CN201510230758.9A CN105031605A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23327509P 2009-08-12 2009-08-12
US61/233,275 2009-08-12
PCT/US2010/045160 WO2011019809A1 (en) 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201510230758.9A Division CN105031605A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法
CN201710423699.6A Division CN107412724A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法

Publications (1)

Publication Number Publication Date
CN102647994A true CN102647994A (zh) 2012-08-22

Family

ID=43586452

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010800461915A Pending CN102647994A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法
CN201510230758.9A Pending CN105031605A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法
CN201710423699.6A Pending CN107412724A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510230758.9A Pending CN105031605A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法
CN201710423699.6A Pending CN107412724A (zh) 2009-08-12 2010-08-11 预防或治疗代谢综合症的方法

Country Status (10)

Country Link
US (4) US20110039766A1 (enExample)
EP (4) EP3427746A1 (enExample)
JP (5) JP5909182B2 (enExample)
CN (3) CN102647994A (enExample)
CA (1) CA2770688C (enExample)
DK (1) DK2464371T3 (enExample)
ES (1) ES2576746T3 (enExample)
HK (1) HK1247820A1 (enExample)
HU (1) HUE029550T2 (enExample)
WO (1) WO2011019809A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102760A (zh) * 2013-09-27 2016-11-09 康奈尔大学 芳香族阳离子肽用于治疗胆固醇诱发的线粒体功能障碍的用途
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3708178T1 (sl) 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP3603658B1 (en) * 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
EP4397314B1 (en) * 2012-10-22 2025-12-03 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
HK1215934A1 (zh) * 2012-12-06 2016-09-30 Stealth Peptides International, Inc. 肽治疗剂及其使用方法
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
WO2017066659A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Jag1 expression predicts therapeutic response in nash
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
JP7171671B2 (ja) * 2020-10-22 2022-11-15 野村マイクロ・サイエンス株式会社 超純水製造システム及び超純水製造方法
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
US20070110728A1 (en) * 2003-11-28 2007-05-17 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
US20080125403A1 (en) * 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) * 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP3167935B1 (en) * 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
EP3603658B1 (en) * 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070110728A1 (en) * 2003-11-28 2007-05-17 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
US20080125403A1 (en) * 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102760A (zh) * 2013-09-27 2016-11-09 康奈尔大学 芳香族阳离子肽用于治疗胆固醇诱发的线粒体功能障碍的用途
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
CN108210896A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗高脂血症的药物及其用途
CN108210898A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪异常沉积导致的组织损伤的药物及其用途
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver

Also Published As

Publication number Publication date
US20160199435A1 (en) 2016-07-14
ES2576746T3 (es) 2016-07-11
JP5909182B2 (ja) 2016-04-26
HUE029550T2 (en) 2017-03-28
CA2770688C (en) 2018-06-05
EP2464371A4 (en) 2013-02-20
CN107412724A (zh) 2017-12-01
JP2019104768A (ja) 2019-06-27
JP2013501802A (ja) 2013-01-17
EP2464371B1 (en) 2016-03-16
US20180104304A1 (en) 2018-04-19
US20190209641A1 (en) 2019-07-11
WO2011019809A1 (en) 2011-02-17
JP2018052983A (ja) 2018-04-05
CA2770688A1 (en) 2011-02-17
EP3067061A1 (en) 2016-09-14
HK1247820A1 (zh) 2018-10-05
JP6271785B2 (ja) 2018-01-31
JP2016041762A (ja) 2016-03-31
EP3427746A1 (en) 2019-01-16
CN105031605A (zh) 2015-11-11
US20110039766A1 (en) 2011-02-17
EP3251686A1 (en) 2017-12-06
JP2017132782A (ja) 2017-08-03
DK2464371T3 (en) 2016-06-27
EP2464371A1 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
JP6271785B2 (ja) 代謝性症候群を予防し又は治療するための方法
US20230285499A1 (en) Methods for the prevention or treatment of heart failure
CN104922653A (zh) 治疗或预防哺乳动物对象中骨骼肌衰弱的方法
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
HK1174844A (en) Methods for preventing or treating metabolic syndrome
HK1242194A1 (en) Methods for preventing or treating metabolic syndrome
HK1224948A1 (en) Methods for preventing or treating metabolic syndrome
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174844

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120822